BioTime to Present at the Ladenburg Thalmann 2017 Healthcare Conference
September 20 2017 - 7:00AM
Business Wire
BioTime, Inc. (NYSE American: BTX), a clinical-stage
biotechnology company focused on developing and commercializing
products addressing degenerative diseases, today announced that Adi
Mohanty, Co-Chief Executive Officer, and Russell Skibsted, Chief
Financial Officer, will present at the Ladenburg Thalmann 2017
Healthcare Conference in New York. Mr. Mohanty will provide an
overview of the Company in his presentation on Tuesday, September
26, 2017 at 2:00 pm ET/11:00 am PT.
A live webcast and subsequent archived replay of the Company’s
presentation may be accessed via the investor relations section of
the Company’s website at www.biotimeinc.com.
About BioTime, Inc.
BioTime is a clinical-stage biotechnology company focused on
developing and commercializing products addressing degenerative
diseases. The Company’s current clinical programs are targeting
three primary sectors, aesthetics, ophthalmology and cell/drug
delivery. Its clinical programs are based on two platform
technologies: pluripotent cells and cell/drug delivery. The
foundation of BioTime’s core therapeutic technology platform is
pluripotent cells that are capable of becoming any of the cell
types in the human body. The foundation of the Company’s cell
delivery platform is its HyStem® cell and drug delivery matrix
technology. BioTime also has significant equity holdings in two
publicly traded companies, Asterias Biotherapeutics, Inc. and
OncoCyte Corporation, and one private company, AgeX
Therapeutics.
BioTime common stock is traded on the NYSE American and TASE
under the symbol BTX. For more information, please
visit www.biotimeinc.com or connect with the company
on Twitter, LinkedIn, Facebook, YouTube,
and Google+.
To receive ongoing BioTime corporate communications, please
click on the following link to join the Company’s email alert list:
http://news.biotimeinc.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170920005374/en/
Investor Contact:BioTimeDavid Nakasone,
510-871-4188Dnakasone@biotimeinc.comorMedia Contact:JQA
Partners, Inc.Jules Abraham,
917-885-7378jabraham@jqapartners.com
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Apr 2023 to Apr 2024